What is Avita Medical's operating income?

Avita Medical's total operating income in 2025 was -$42.53 million, based on the following breakdown: Total Gross Profit: $58.82 million Total Operating Expenses: $101.35 million

Avita Medical (RCEL) Financials

$10.09 -0.25 (-2.42%)

Closing price 04:00 PM Eastern

Extended Trading

$10.07 -0.02 (-0.15%)

As of 05:57 PM Eastern

Compare

Annual Income Statements for Avita Medical

This table shows Avita Medical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	6/30/2017	6/30/2018	6/30/2019	6/30/2020	6/30/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-9.05	-13	-25	-42	-27	-27	-35	-62	-49
Consolidated Net Income / (Loss)	-9.05	-13	-25	-42	-27	-27	-35	-62	-49
Net Income / (Loss) Continuing Operations	-9.05	-13	-25	-42	-27	-27	-35	-62	-49
Total Pre-Tax Income	-9.86	-14	-25	-42	-27	-27	-35	-62	-49
Total Operating Income	-15	-14	-26	-43	-27	-28	-43	-57	-43
Total Gross Profit	-0.89	0.38	4.20	11	23	28	42	55	59
Total Revenue	0.00	0.93	5.47	14	29	34	50	64	72
Operating Revenue	-	0.93	5.47	14	29	34	50	64	72
Total Cost of Revenue	0.89	0.55	1.27	2.97	5.95	6.04	7.78	9.09	13
Operating Cost of Revenue	0.89	0.55	1.27	2.97	5.95	6.04	7.78	9.09	13
Total Operating Expenses	14	14	30	58	50	56	85	112	101
Selling, General & Admin Expense	1.74	9.40	15	33	22	23	28	33	27
Marketing Expense	4.00	4.88	13	16	15	22	37	58	53
Research & Development Expense	8.58	6.26	8.00	9.16	15	14	21	20	21
Other Operating Expenses / (Income)	-	-7.73	-5.92	-3.93	-2.06	-3.22	-1.43	0.00	0.00
Total Other Income / (Expense), net	5.35	0.03	0.31	0.65	-0.01	0.88	7.34	-5.20	-6.04
Interest Expense	-	0.02	0.03	0.03	0.02	0.02	1.14	5.36	5.00
Other Income / (Expense), net	0.06	0.05	0.33	0.69	0.02	0.89	8.48	0.16	-1.04
Income Tax Expense	-0.81	-1.07	-0.12	0.00	0.04	0.04	0.07	0.05	0.01
Basic Earnings per Share	-	$1.37	$1.56	$2.07	$1.17	$1.07	($1.40)	($2.39)	($1.74)
Weighted Average Basic Shares Outstanding	-	9.33M	16.06M	20.29M	22.67M	25.00M	25.33M	25.88M	27.86M
Diluted Earnings per Share	-	$1.37	$1.56	$2.07	$1.17	$1.07	($1.40)	($2.39)	($1.74)
Weighted Average Diluted Shares Outstanding	-	9.33M	16.06M	20.29M	22.67M	25.00M	25.33M	25.88M	27.86M
Weighted Average Basic & Diluted Shares Outstanding	-	-	1.90B	21.47M	24.90M	25.30M	25.71M	26.36M	30.63M

This table shows Avita Medical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
Net Income / (Loss) Attributable to Common Shareholders	-7.07	-19	-15	-16	-12	-14	-9.92	-13	-12	-11	-7.66
Consolidated Net Income / (Loss)	-7.07	-19	-15	-16	-12	-14	-9.92	-13	-12	-11	-7.66
Net Income / (Loss) Continuing Operations	-7.07	-19	-15	-16	-12	-14	-9.92	-13	-12	-11	-7.66
Total Pre-Tax Income	-7.05	-19	-15	-16	-12	-14	-9.92	-13	-12	-11	-7.63
Total Operating Income	-12	-17	-16	-14	-9.96	-12	-11	-9.15	-10	-8.80	-6.86
Total Gross Profit	12	9.59	13	16	16	16	15	14	14	16	18
Total Revenue	14	11	15	20	18	19	18	17	18	19	22
Operating Revenue	14	11	15	20	18	19	18	17	18	19	22
Total Cost of Revenue	1.80	1.51	2.11	3.19	2.28	2.83	3.47	3.19	3.31	3.52	3.94
Operating Cost of Revenue	1.80	1.51	2.11	3.19	2.28	2.83	3.47	3.19	3.31	3.52	3.94
Total Operating Expenses	25	27	29	30	26	28	26	23	25	25	25
Selling, General & Admin Expense	7.75	8.96	7.52	9.59	7.12	6.39	6.67	7.23	7.09	6.06	5.97
Marketing Expense	10	13	16	15	14	15	14	12	12	13	14
Research & Development Expense	6.77	5.19	4.89	5.43	4.85	6.28	5.12	3.75	5.69	5.63	5.08
Total Other Income / (Expense), net	5.22	-1.42	0.26	-2.43	-1.61	-2.02	1.23	-4.02	-1.23	-1.82	-0.78
Interest Expense	1.12	1.36	1.35	1.36	1.30	1.23	1.25	1.27	1.25	1.42	1.46
Other Income / (Expense), net	6.34	-0.07	1.61	-1.07	-0.31	-0.79	2.48	-2.75	0.02	-0.40	0.69
Income Tax Expense	0.01	0.03	0.03	-0.03	0.02	0.01	0.00	0.02	-0.02	-0.01	0.03
Basic Earnings per Share	($0.28)	($0.73)	($0.60)	($0.62)	($0.44)	($0.53)	($0.38)	($0.46)	($0.37)	($0.35)	($0.25)
Weighted Average Basic Shares Outstanding	25.33M	25.64M	25.76M	25.98M	25.88M	26.25M	26.37M	28.39M	27.86M	30.54M	30.75M
Diluted Earnings per Share	($0.28)	($0.73)	($0.60)	($0.62)	($0.44)	($0.53)	($0.38)	($0.46)	($0.37)	($0.35)	($0.25)
Weighted Average Diluted Shares Outstanding	25.33M	25.64M	25.76M	25.98M	25.88M	26.25M	26.37M	28.39M	27.86M	30.54M	30.75M
Weighted Average Basic & Diluted Shares Outstanding	25.71M	25.80M	25.99M	26.22M	26.36M	26.43M	26.62M	30.49M	30.63M	30.78M	30.93M

This table details how cash moves in and out of Avita Medical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	6/30/2017	6/30/2018	6/30/2019	6/30/2020	6/30/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-0.10	8.07	9.39	53	37	-38	3.95	-8.07	-3.81
Net Cash From Operating Activities	-9.66	-13	-19	-23	-26	-19	-38	-49	-31
Net Cash From Continuing Operating Activities	-9.66	-13	-19	-23	-26	-19	-38	-49	-31
Net Income / (Loss) Continuing Operations	-0.71	-13	-25	-42	-27	-27	-35	-62	-49
Consolidated Net Income / (Loss)	0.71	-13	-25	-42	-27	-27	-35	-62	-49
Depreciation Expense	-	0.11	0.27	0.47	0.72	0.57	0.63	1.13	2.35
Amortization Expense	-	-	0.00	0.00	0.13	0.06	-1.04	-1.67	-0.31
Non-Cash Adjustments To Reconcile Net Income	18	0.50	2.22	17	6.85	6.81	3.53	18	12
Changes in Operating Assets and Liabilities, net	-	-0.83	3.27	1.33	-7.01	0.14	-5.76	-4.41	3.03
Net Cash From Investing Activities	0.15	-0.37	-1.23	-0.85	-1.17	-19	1.61	37	12
Net Cash From Continuing Investing Activities	0.15	-0.37	-1.23	-0.85	-1.17	-19	1.61	37	12
Purchase of Property, Plant & Equipment	-	-0.37	-1.02	-0.59	-0.89	-0.45	-1.38	-9.17	-1.64
Acquisitions	-	0.00	-0.21	-0.26	-0.28	-0.07	-0.07	-0.16	-0.10
Purchase of Investments	-	-	-	0.00	0.00	-74	-79	-25	-13
Sale and/or Maturity of Investments	-	-	-	-	0.00	56	82	71	28
Net Cash From Financing Activities	7.70	21	30	77	64	0.90	40	3.51	15
Net Cash From Continuing Financing Activities	7.70	21	30	77	64	0.90	40	3.51	15
Repayment of Debt	-	-0.06	-0.06	-0.04	-0.01	-	-	0.00	-1.06
Issuance of Common Equity	-	23	32	82	69	-	-	0.00	15
Other Financing Activities, net	0.75	0.00	0.25	0.47	0.06	0.90	1.61	3.51	1.20
Effect of Exchange Rate Changes	-	0.10	0.16	-	0.13	-0.03	-0.02	0.00	0.00
Cash Interest Paid	0.01	0.02	0.03	0.04	0.00	0.02	1.14	5.36	4.98
Cash Income Taxes Paid	-	-	0.00	0.00	0.04	0.02	0.04	0.04	0.02

This table details how cash moves in and out of Avita Medical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
Net Change in Cash & Equivalents	-29	-5.17	0.50	1.19	-4.59	0.82	-2.65	3.21	-5.18	-1.93	0.83
Net Cash From Operating Activities	-11	-21	-13	-7.21	-8.08	-10	-10	-5.22	-5.44	-10	-3.50
Net Cash From Continuing Operating Activities	-11	-21	-13	-7.21	-8.07	-10	-10	-5.21	-5.44	-10	-3.50
Net Income / (Loss) Continuing Operations	-7.07	-19	-15	-16	-12	-14	-9.92	-13	-12	-11	-7.66
Consolidated Net Income / (Loss)	-7.07	-19	-15	-16	-12	-14	-9.92	-13	-12	-11	-7.66
Depreciation Expense	0.19	0.20	0.20	0.31	0.41	0.52	0.55	0.57	0.70	0.63	0.61
Amortization Expense	-0.50	-0.68	-0.48	-0.33	-0.20	-0.13	-0.07	-0.03	-0.08	-0.08	-0.04
Non-Cash Adjustments To Reconcile Net Income	-3.81	4.30	1.34	4.86	4.02	3.41	1.39	9.48	-1.47	2.22	2.59
Changes in Operating Assets and Liabilities, net	0.32	-6.03	1.54	4.15	-0.71	-0.25	-2.19	-2.05	7.03	-2.23	1.01
Net Cash From Investing Activities	-57	15	12	7.39	2.47	11	7.02	-5.34	0.01	2.04	3.89
Net Cash From Continuing Investing Activities	-57	15	12	7.39	2.47	11	7.02	-5.34	0.01	2.04	3.89
Purchase of Property, Plant & Equipment	-0.30	-1.15	-2.65	-3.76	-1.61	-0.22	-0.52	-0.93	0.04	-0.02	-0.11
Acquisitions	-0.03	-0.08	-0.00	-0.06	-0.02	-0.01	-	-0.02	-0.07	-0.00	-0.00
Sale and/or Maturity of Investments	14	19	18	24	10	11	11	3.50	2.00	6.00	4.00
Net Cash From Financing Activities	39	0.63	0.85	1.01	1.02	0.36	0.56	14	0.25	6.10	0.44
Net Cash From Continuing Financing Activities	39	0.63	0.85	1.01	1.02	0.36	0.56	14	0.25	6.10	0.44
Other Financing Activities, net	0.67	0.63	0.85	1.01	1.02	0.36	0.56	0.03	0.25	0.00	0.44
Cash Interest Paid	1.12	1.36	1.35	1.36	1.30	1.23	1.25	1.26	1.24	1.42	1.45
Cash Income Taxes Paid	-	0.02	0.00	0.00	0.02	0.00	-	-	0.02	0.00	0.04

This table presents Avita Medical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	6/30/2018	6/30/2019	6/30/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	17	26	82	116	98	112	80	56
Total Current Assets	17	24	78	92	87	104	57	35
Cash & Equivalents	11	20	74	56	18	22	14	10
Short-Term Investments	-	-	0.00	30	61	67	22	7.94
Accounts Receivable	4.03	1.79	2.43	3.43	4.41	7.69	12	9.09
Inventories, net	0.86	0.74	1.13	2.13	2.13	5.60	7.27	6.93
Prepaid Expenses	-	1.10	0.99	1.21	1.58	1.66	2.06	1.29
Plant, Property, & Equipment, net	107	1.31	1.36	1.26	1.20	1.88	10	8.63
Total Noncurrent Assets	14	0.35	2.71	22	9.61	5.76	13	12
Intangible Assets	-	0.23	0.36	0.44	0.47	0.49	5.57	5.65
Other Noncurrent Operating Assets	14	0.13	2.35	2.18	2.21	5.27	7.12	6.63
Total Liabilities & Shareholders' Equity	138	26	82	116	98	112	80	56
Total Liabilities	2.98	4.95	10	11	13	62	75	73
Total Current Liabilities	0.00	4.48	7.71	9.15	11	13	20	63
Short-Term Debt	-	-	-	-	-	-	0.00	43
Accounts Payable	-	1.92	4.33	2.71	3.00	3.79	6.29	8.96
Accrued Expenses	-	-	-	-	-	-	-	7.81
Current Deferred Revenue	-	-	-	-	0.08	0.17	2.09	0.28
Other Current Liabilities	-	0.44	0.56	1.08	0.99	1.27	1.32	2.65
Total Noncurrent Liabilities	2.98	0.47	2.35	1.98	2.83	49	55	10
Noncurrent Employee Benefit Liabilities	-	-	-	-	0.56	0.69	0.24	3.70
Other Noncurrent Operating Liabilities	2.88	0.47	0.44	1.07	1.97	7.18	9.73	6.67
Commitments & Contingencies	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	135	21	72	105	85	49	4.50	-17
Total Preferred & Common Equity	135	21	72	105	85	49	4.50	-17
Preferred Stock	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	135	21	72	105	85	49	4.50	-17
Common Stock	121	165	259	332	340	350	368	394
Retained Earnings	-	-153	-195	-236	-263	-298	-360	-408
Accumulated Other Comprehensive Income / (Loss)	-	8.18	8.15	8.06	7.63	-1.89	-1.94	-1.37
Other Equity Adjustments	14	-	-	-	-0.13	-1.13	-1.32	-1.29

This table presents Avita Medical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026	Q2 2026
Period end date	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026	6/30/2026
Total Assets	81	97	88	81	70	58	64	52	48
Total Current Assets	74	86	73	64	48	36	41	32	28
Cash & Equivalents	51	17	17	19	15	12	15	8.31	9.14
Short-Term Investments	9.26	51	37	26	11	3.47	7.89	5.95	2.00
Accounts Receivable	6.08	7.11	8.81	10	12	11	9.01	9.89	9.87
Inventories, net	4.38	7.17	6.71	6.23	8.40	7.54	7.24	6.12	5.29
Prepaid Expenses	3.36	3.52	3.38	2.89	1.71	1.68	1.80	1.38	2.11
Plant, Property, & Equipment, net	1.86	4.30	7.02	9.15	9.89	9.69	9.88	8.21	7.68
Total Noncurrent Assets	5.23	7.10	7.84	7.98	12	12	12	12	12
Intangible Assets	0.46	0.54	0.55	0.59	5.45	5.31	5.20	5.44	5.25
Other Noncurrent Operating Assets	4.77	6.56	7.30	7.39	6.25	6.88	7.27	6.24	6.46
Total Liabilities & Shareholders' Equity	81	97	88	81	70	58	64	52	48
Total Liabilities	17	64	64	69	74	71	70	75	76
Total Current Liabilities	12	12	14	17	23	63	62	67	69
Short-Term Debt	-	-	-	-	3.00	3.00	45	49	50
Accounts Payable	3.02	4.48	4.16	4.19	8.68	7.27	8.11	7.22	6.42
Accrued Expenses	-	-	-	-	-	-	-	-	8.82
Current Deferred Revenue	0.33	-	0.75	1.87	0.50	0.34	0.33	0.28	0.51
Other Current Liabilities	1.34	5.18	1.26	1.31	2.44	1.84	2.15	2.17	3.31
Total Noncurrent Liabilities	6.20	49	50	52	51	51	8.56	8.04	6.90
Noncurrent Employee Benefit Liabilities	3.99	4.74	0.40	0.22	0.06	0.05	0.00	-	3.93
Other Noncurrent Operating Liabilities	0.37	0.35	5.46	5.83	7.03	6.01	6.24	6.06	2.97
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	63	33	24	12	-4.57	-13	-6.67	-23	-28
Total Preferred & Common Equity	63	33	24	12	-4.57	-13	-6.67	-23	-28
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	63	33	24	12	-4.57	-13	-6.67	-23	-28
Common Stock	347	353	359	364	371	374	393	396	400
Retained Earnings	-291	-317	-332	-348	-374	-384	-397	-419	-427
Accumulated Other Comprehensive Income / (Loss)	7.98	-3.07	-1.56	-2.07	-0.41	-2.08	-1.39	0.65	-0.08
Other Equity Adjustments	-1.29	-0.94	-1.02	-1.26	-1.31	-1.30	-1.28	-0.64	-0.63

This table displays calculated financial ratios and metrics derived from Avita Medical's official financial filings.

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	6/30/2017	6/30/2018	6/30/2019	6/30/2020	6/30/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	489.24%	160.56%	104.95%	17.75%	45.68%	28.14%	11.45%
EBITDA Growth	0.00%	9.72%	-82.24%	-66.60%	38.16%	-1.20%	-33.06%	-64.77%	27.11%
EBIT Growth	0.00%	8.99%	-82.74%	-66.67%	36.84%	-0.34%	-28.40%	-65.14%	22.79%
NOPAT Growth	0.00%	9.01%	-84.44%	-67.19%	37.81%	-3.64%	-55.08%	-32.68%	24.84%
Net Income Growth	0.00%	-40.70%	-97.11%	-67.44%	36.75%	-0.31%	-32.69%	-74.80%	21.44%
EPS Growth	0.00%	0.00%	13.87%	32.69%	-43.48%	-8.55%	-230.84%	-70.71%	27.20%
Operating Cash Flow Growth	0.00%	-34.19%	-48.53%	-18.17%	-13.87%	26.30%	-99.11%	-28.75%	36.26%
Free Cash Flow Firm Growth	0.00%	0.00%	178.98%	-128.40%	37.96%	5.21%	-85.42%	-58.91%	49.12%
Invested Capital Growth	0.00%	0.00%	-99.63%	4.37%	-6.49%	-374.27%	223.41%	805.42%	-24.93%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	11.31%	8.19%	10.44%	7.01%	-1.09%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	0.00%	21.65%	0.84%	-2.57%	-7.17%	0.69%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	21.41%	1.32%	-1.81%	-8.33%	-0.26%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	21.69%	-0.86%	-17.54%	3.93%	-1.07%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	0.00%	21.37%	1.25%	-5.08%	-7.89%	-0.07%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-39.38%	-3.60%	-55.56%	-519.30%	3.87%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-35.98%	32.84%	-24.28%	5.38%	7.81%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	-16.99%	-7.56%	-3.65%	22.03%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-88.43%	-519.19%	-67.84%	1.87%	-42.21%
Profitability Metrics	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	41.23%	76.78%	79.16%	79.65%	82.45%	84.48%	85.85%	82.13%
EBITDA Margin	0.00%	-1,472.34%	-455.37%	-291.16%	-87.85%	-75.50%	-68.96%	-88.68%	-58.00%
Operating Margin	0.00%	-1,489.88%	-466.35%	-299.23%	-90.79%	-79.91%	-85.07%	-88.08%	-59.40%
EBIT Margin	0.00%	-1,484.18%	-460.29%	-294.42%	-90.73%	-77.32%	-68.15%	-87.83%	-60.85%
Profit (Net Income) Margin	0.00%	-1,370.83%	-458.57%	-294.68%	-90.94%	-77.47%	-70.56%	-96.26%	-67.85%
Tax Burden Percent	91.83%	92.22%	99.52%	100.01%	100.14%	100.14%	100.19%	100.09%	100.02%
Interest Burden Percent	65.06%	100.15%	100.11%	100.08%	100.08%	100.06%	103.34%	109.50%	111.48%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-15.68%	-28.81%	-6,383.61%	-4,016.86%	0.00%	-20,807.32%	-520.84%	-248.29%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	38.80%	17.02%	-6,357.27%	-4,007.77%	0.00%	-20,799.04%	-404.89%	-352.42%
Return on Net Nonoperating Assets (RNNOA)	0.00%	-3.22%	-3.45%	6,293.45%	3,986.83%	0.00%	20,754.43%	289.88%	1,048.01%
Return on Equity (ROE)	0.00%	-18.90%	-32.26%	-90.16%	-30.03%	-28.16%	-52.89%	-230.96%	799.72%
Cash Return on Invested Capital (CROIC)	0.00%	-215.68%	169.71%	-6,387.88%	-4,010.16%	0.00%	-2,154.49%	-681.06%	-219.81%
Operating Return on Assets (OROA)	0.00%	-80.81%	-117.61%	-77.59%	-26.73%	-24.84%	-32.56%	-58.98%	-64.03%
Return on Assets (ROA)	0.00%	-74.64%	-117.17%	-77.66%	-26.79%	-24.89%	-33.71%	-64.64%	-71.40%
Return on Common Equity (ROCE)	0.00%	-18.90%	-32.26%	-90.16%	-30.03%	-28.16%	-52.89%	-230.96%	799.72%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-9.45%	-120.50%	-58.05%	-25.41%	-31.47%	-72.12%	-1,374.64%	0.00%
Net Operating Profit after Tax (NOPAT)	-11	-9.69	-18	-30	-19	-19	-30	-40	-30
NOPAT Margin	0.00%	-1,042.92%	-326.45%	-209.46%	-63.55%	-55.94%	-59.55%	-61.66%	-41.58%
Net Nonoperating Expense Percent (NNEP)	0.00%	-54.48%	-45.84%	-26.34%	-9.09%	-7.80%	-8.27%	-115.95%	104.13%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-32.97%	-79.89%	-104.58%
Cost of Revenue to Revenue	0.00%	58.77%	23.22%	20.84%	20.35%	17.55%	15.52%	14.15%	17.87%
SG&A Expenses to Revenue	0.00%	1,012.16%	275.83%	231.54%	76.63%	67.78%	56.51%	51.66%	38.23%
R&D to Revenue	0.00%	673.52%	146.22%	64.25%	50.69%	40.26%	41.52%	31.69%	29.10%
Operating Expenses to Revenue	0.00%	1,531.11%	543.13%	405.91%	170.44%	162.36%	169.55%	173.93%	141.53%
Earnings before Interest and Taxes (EBIT)	-15	-14	-25	-42	-27	-27	-34	-56	-44
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-15	-14	-25	-42	-26	-26	-35	-57	-42
Valuation Ratios	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	40.01	0.24	0.10	0.36	3.73	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	40.21	0.24	0.10	0.36	0.00	0.00
Price to Revenue (P/Rev)	0.00	0.00	0.00	203.07	0.87	0.24	0.35	0.26	0.07
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	5,909.03	0.00	0.00	0.00	1.90	3.13
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	198.03	0.00	0.00	0.00	0.40	0.45
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.03	0.01	0.00	0.85	10.02	-2.71
Long-Term Debt to Equity	0.00	0.00	0.00	0.03	0.01	0.00	0.85	10.02	-0.13
Financial Leverage	0.00	-0.08	-0.20	-0.99	-0.99	-1.00	-1.00	-0.72	-2.97
Leverage Ratio	0.00	0.13	0.28	1.16	1.12	1.13	1.57	3.57	-11.20
Compound Leverage Factor	0.00	0.13	0.28	1.16	1.12	1.13	1.62	3.91	-12.49
Debt to Total Capital	0.00%	0.07%	0.00%	2.58%	0.87%	0.36%	45.84%	90.93%	158.48%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	150.99%
Long-Term Debt to Total Capital	0.00%	0.07%	0.00%	2.58%	0.87%	0.36%	45.84%	90.93%	7.50%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	99.93%	100.00%	97.42%	99.13%	99.64%	54.16%	9.07%	-58.48%
Debt to EBITDA	0.00	-0.01	0.00	-0.05	-0.04	-0.01	-1.20	-0.79	-1.09
Net Debt to EBITDA	0.00	0.80	0.00	1.73	4.06	3.31	1.37	-0.16	-0.65
Long-Term Debt to EBITDA	0.00	-0.01	0.00	-0.05	-0.04	-0.01	-1.20	-0.79	-0.05
Debt to NOPAT	0.00	-0.01	0.00	-0.06	-0.05	-0.02	-1.39	-1.14	-1.52
Net Debt to NOPAT	0.00	1.12	0.00	2.41	5.61	4.47	1.59	-0.23	-0.90
Long-Term Debt to NOPAT	0.00	-0.01	0.00	-0.06	-0.05	-0.02	-1.39	-1.14	-0.07
Altman Z-Score	0.00	0.00	0.00	168.94	-1.15	-2.97	-3.15	-7.16	-11.95
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-
Current Ratio	0.00	0.00	5.38	10.17	10.07	8.18	7.88	2.83	0.57
Quick Ratio	0.00	0.00	4.90	9.87	9.69	7.83	7.33	2.37	0.44
Cash Flow Metrics	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-133	105	-30	-19	-18	-33	-52	-26
Operating Cash Flow to CapEx	0.00%	-3,550.68%	-1,885.41%	-3,855.42%	-2,897.20%	-4,223.45%	-2,752.43%	-533.63%	-1,902.13%
Free Cash Flow to Firm to Interest Expense	0.00	-6,346.37	3,898.42	-905.92	-843.05	-1,098.78	-28.52	-9.66	-5.27
Operating Cash Flow to Interest Expense	0.00	-617.14	-712.96	-689.30	-1,177.32	-1,193.13	-33.26	-9.13	-6.23
Operating Cash Flow Less CapEx to Interest Expense	0.00	-634.52	-750.78	-707.18	-1,217.95	-1,221.38	-34.46	-10.84	-6.56
Efficiency Ratios	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.05	0.26	0.26	0.29	0.32	0.48	0.67	1.05
Accounts Receivable Turnover	0.00	0.23	1.88	6.76	9.98	8.78	8.28	6.58	6.86
Inventory Turnover	0.00	0.64	1.59	3.18	3.65	2.84	2.02	1.41	1.80
Fixed Asset Turnover	0.00	0.01	0.10	10.68	22.27	27.96	32.59	10.80	7.68
Accounts Payable Turnover	0.00	0.00	0.00	0.95	1.69	2.12	2.29	1.80	1.68
Days Sales Outstanding (DSO)	0.00	1,583.65	193.89	53.96	36.57	41.56	44.06	55.49	53.19
Days Inventory Outstanding (DIO)	0.00	572.78	229.57	114.61	99.92	128.60	181.12	258.18	202.48
Days Payable Outstanding (DPO)	0.00	0.00	0.00	383.60	216.00	172.50	159.39	202.43	217.58
Cash Conversion Cycle (CCC)	0.00	2,156.43	423.46	-215.03	-79.51	-2.33	65.79	111.24	38.10
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-
Invested Capital	0.00	124	0.46	0.48	0.45	-1.23	1.51	14	10
Invested Capital Turnover	0.00	0.02	0.09	30.48	63.20	-88.37	349.43	8.45	5.97
Increase / (Decrease) in Invested Capital	0.00	124	-123	0.02	-0.03	-1.67	2.74	12	-3.42
Enterprise Value (EV)	0.00	0.00	0.00	2,825	-79	-78	-30	26	32
Market Capitalization	0.00	0.00	0.00	2,896	25	8.26	18	17	5.26
Book Value per Share	$0.00	$14.45	$1.30	$0.04	$4.21	$3.39	$1.92	$0.17	($0.55)
Tangible Book Value per Share	$0.00	$14.45	$1.28	$0.04	$4.19	$3.37	$1.90	($0.04)	($0.73)
Total Capital	0.00	135	21	74	106	85	91	50	28
Total Debt	0.00	0.10	0.00	1.92	0.92	0.31	42	45	45
Total Long-Term Debt	0.00	0.10	0.00	1.92	0.92	0.31	42	45	2.14
Net Debt	0.00	-11	-20	-72	-104	-86	-48	9.20	27
Capital Expenditures (CapEx)	-0.82	0.37	1.02	0.59	0.89	0.45	1.38	9.17	1.64
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	5.52	-0.73	-3.16	-2.38	-2.58	1.75	0.96	-2.39
Debt-free Net Working Capital (DFNWC)	0.00	17	20	71	83	77	91	37	16
Net Working Capital (NWC)	0.00	17	20	71	83	77	91	37	-27
Net Nonoperating Expense (NNE)	-1.60	3.05	7.23	12	8.01	7.41	5.52	22	19
Net Nonoperating Obligations (NNO)	0.00	-11	-20	-72	-104	-86	-48	9.20	27
Total Depreciation and Amortization (D&A)	0.00	0.11	0.27	0.47	0.84	0.63	-0.41	-0.55	2.04
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	594.39%	-13.34%	-22.17%	-8.12%	-7.49%	3.49%	1.49%	-3.33%
Debt-free Net Working Capital to Revenue	0.00%	1,777.40%	358.86%	495.53%	283.89%	223.02%	181.10%	57.34%	22.06%
Net Working Capital to Revenue	0.00%	1,777.40%	358.86%	495.53%	283.89%	223.02%	181.10%	57.34%	-37.97%
Earnings Adjustments	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	$0.00	$1.17	$1.07	$1.40	($2.39)	($1.74)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	1.90B	0.00	22.67M	25.00M	25.33M	25.88M	27.86M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$1.17	$1.07	$1.40	($2.39)	($1.74)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	1.90B	0.00	22.67M	25.00M	25.33M	25.88M	27.86M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	1.90B	0.00	24.90M	25.30M	25.71M	26.36M	30.63M
Normalized Net Operating Profit after Tax (NOPAT)	-11	-8.69	-18	-30	-19	-19	-30	-40	-30
Normalized NOPAT Margin	0.00%	-935.69%	-326.45%	-209.46%	-63.55%	-55.94%	-59.55%	-61.66%	-41.58%
Pre Tax Income Margin	0.00%	-1,486.44%	-460.78%	-294.65%	-90.81%	-77.36%	-70.43%	-96.17%	-67.83%
Debt Service Ratios	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	-656.57	-933.19	-1,272.52	-1,205.59	-1,663.31	-29.90	-10.53	-8.71
NOPAT to Interest Expense	0.00	-461.37	-661.84	-905.31	-844.45	-1,203.34	-26.12	-7.39	-5.95
EBIT Less CapEx to Interest Expense	0.00	-673.95	-971.00	-1,290.39	-1,246.23	-1,691.56	-31.11	-12.24	-9.04
NOPAT Less CapEx to Interest Expense	0.00	-478.75	-699.65	-923.19	-885.09	-1,231.59	-27.33	-9.10	-6.28
Payout Ratios	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-11.27%	-11.69%	-12.08%	-19.22%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Avita Medical's official financial filings.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
DEI Shares Outstanding	25,550,694.00	25,550,694.00	25,799,735.00	25,989,699.00	-	26,357,542.00	26,434,658.00	26,618,934.00	-	30,631,794.00	30,776,689.00
DEI Adjusted Shares Outstanding	25,550,694.00	25,550,694.00	25,799,735.00	25,989,699.00	-	26,357,542.00	26,434,658.00	26,618,934.00	-	30,631,794.00	30,776,689.00
DEI Earnings Per Adjusted Shares Outstanding	-0.28	-0.73	-0.60	-0.62	-	-0.53	-0.38	-0.50	-	-0.35	-0.25
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	50.13%	5.25%	29.29%	43.25%	29.67%	66.73%	21.21%	-12.71%	-4.29%	3.98%	17.83%
EBITDA Growth	-16.14%	-90.94%	-37.00%	-72.85%	-61.04%	31.11%	42.75%	23.71%	2.85%	29.26%	31.45%
EBIT Growth	-11.42%	-88.03%	-35.21%	-71.14%	-73.17%	26.95%	38.17%	19.97%	-1.12%	27.10%	28.82%
NOPAT Growth	-107.74%	-73.61%	-39.94%	-48.36%	18.87%	31.26%	28.65%	33.70%	-4.51%	25.57%	38.51%
Net Income Growth	-31.98%	-102.36%	-48.24%	-86.01%	-64.03%	25.72%	35.56%	18.62%	-0.28%	23.44%	22.75%
EPS Growth	-227.27%	-97.30%	-46.34%	-82.35%	-57.14%	27.40%	36.67%	25.81%	15.91%	33.96%	34.21%
Operating Cash Flow Growth	-216.15%	-129.96%	-40.42%	19.61%	25.61%	50.59%	19.96%	27.65%	32.71%	2.30%	65.82%
Free Cash Flow Firm Growth	-360.09%	-481.39%	-257.93%	-61.22%	-69.07%	21.45%	47.54%	41.58%	79.80%	80.56%	127.77%
Invested Capital Growth	223.41%	11,046.84%	1,482.19%	185.82%	805.42%	92.92%	34.52%	32.32%	-24.93%	-17.93%	-43.78%
Revenue Q/Q Growth	4.03%	-21.78%	36.84%	28.63%	-5.83%	0.59%	-0.52%	-7.36%	3.25%	9.28%	12.73%
EBITDA Q/Q Growth	27.51%	-184.16%	19.51%	-4.25%	32.46%	-21.56%	33.11%	-38.94%	14.00%	11.48%	35.19%
EBIT Q/Q Growth	31.76%	-191.22%	18.87%	-6.14%	30.95%	-22.85%	31.34%	-37.40%	12.75%	11.44%	32.95%
NOPAT Q/Q Growth	-31.88%	-40.19%	9.19%	11.64%	27.88%	-18.78%	5.74%	17.90%	-13.69%	15.40%	22.13%
Net Income Q/Q Growth	18.91%	-164.09%	17.50%	-5.28%	28.49%	-19.59%	28.42%	-32.93%	11.88%	8.69%	27.78%
EPS Q/Q Growth	17.65%	-160.71%	17.81%	-3.33%	29.03%	-20.45%	28.30%	-21.05%	19.57%	5.41%	28.57%
Operating Cash Flow Q/Q Growth	-21.05%	-92.06%	38.75%	43.55%	-12.02%	-27.57%	0.78%	48.98%	-4.20%	-85.22%	65.29%
Free Cash Flow Firm Q/Q Growth	0.76%	-83.33%	-16.38%	23.85%	-4.07%	14.83%	22.28%	15.20%	64.02%	18.04%	211.05%
Invested Capital Q/Q Growth	-67.84%	471.58%	63.38%	-4.82%	1.87%	21.79%	13.92%	-6.38%	-42.21%	33.15%	-21.96%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	87.35%	86.37%	86.11%	83.68%	87.61%	84.70%	81.17%	81.32%	81.24%	81.70%	81.87%
EBITDA Margin	-43.99%	-159.82%	-94.00%	-76.18%	-54.64%	-66.03%	-44.40%	-66.59%	-55.46%	-44.92%	-25.83%
Operating Margin	-86.46%	-154.95%	-102.82%	-70.63%	-54.10%	-63.88%	-60.53%	-53.65%	-59.07%	-45.73%	-31.59%
EBIT Margin	-41.78%	-155.55%	-92.22%	-76.10%	-55.80%	-68.15%	-47.04%	-69.77%	-58.96%	-47.78%	-28.42%
Profit (Net Income) Margin	-49.77%	-168.03%	-101.30%	-82.91%	-62.96%	-74.86%	-53.86%	-77.29%	-65.97%	-55.12%	-35.31%
Tax Burden Percent	100.17%	100.16%	100.21%	99.83%	100.16%	100.06%	100.04%	100.11%	99.86%	99.90%	100.43%
Interest Burden Percent	118.92%	107.85%	109.61%	109.14%	112.65%	109.77%	114.45%	110.65%	112.05%	115.48%	123.72%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-21,148.12%	-1,283.45%	-518.80%	-327.06%	-319.88%	-253.00%	-191.51%	-174.04%	-246.93%	-152.47%	-112.64%
ROIC Less NNEP Spread (ROIC-NNEP)	-21,150.41%	-1,270.43%	-507.31%	-304.13%	-295.79%	165.61%	-210.65%	-226.85%	-270.93%	-167.78%	-120.78%
Return on Net Nonoperating Assets (RNNOA)	21,105.04%	1,171.58%	424.98%	230.72%	211.77%	-15.77%	-422.56%	-1,047.59%	805.69%	351.53%	208.82%
Return on Equity (ROE)	-43.08%	-111.87%	-93.83%	-96.34%	-108.11%	-268.77%	-614.07%	-1,221.63%	558.76%	199.06%	96.18%
Cash Return on Invested Capital (CROIC)	-2,154.49%	-505.23%	-683.30%	-550.65%	-681.06%	-346.49%	-226.91%	-216.41%	-219.81%	-162.40%	-110.01%
Operating Return on Assets (OROA)	-19.96%	-83.01%	-57.34%	-56.38%	-37.47%	-58.51%	-48.27%	-69.78%	-62.04%	-57.09%	-40.58%
Return on Assets (ROA)	-23.78%	-89.67%	-62.98%	-61.43%	-42.28%	-64.27%	-55.27%	-77.30%	-69.42%	-65.86%	-50.43%
Return on Common Equity (ROCE)	-43.08%	-111.87%	-93.83%	-96.34%	-108.11%	-268.77%	-614.07%	-1,221.63%	558.76%	199.06%	96.18%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-137.61%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-8.59	-12	-11	-9.66	-6.97	-8.28	-7.80	-6.41	-7.28	-6.16	-4.80
NOPAT Margin	-60.52%	-108.47%	-71.98%	-49.44%	-37.87%	-44.72%	-42.37%	-37.55%	-41.35%	-32.01%	-22.11%
Net Nonoperating Expense Percent (NNEP)	2.29%	-13.02%	-11.49%	-22.93%	-24.09%	-418.61%	19.14%	52.80%	24.00%	15.31%	8.14%
Return On Investment Capital (ROIC_SIMPLE)	-9.49%	-15.76%	-16.04%	-16.70%	-14.06%	-19.48%	-22.49%	-15.59%	-25.59%	-22.04%	-21.99%
Cost of Revenue to Revenue	12.65%	13.63%	13.89%	16.32%	12.39%	15.30%	18.83%	18.68%	18.76%	18.30%	18.13%
SG&A Expenses to Revenue	54.60%	80.72%	49.48%	49.06%	38.70%	34.51%	36.19%	42.36%	40.25%	31.48%	27.51%
R&D to Revenue	47.66%	46.78%	32.16%	27.77%	26.36%	33.94%	27.78%	21.97%	32.30%	29.24%	23.40%
Operating Expenses to Revenue	173.81%	241.33%	188.93%	154.31%	141.71%	148.58%	141.69%	134.97%	140.31%	127.43%	113.46%
Earnings before Interest and Taxes (EBIT)	-5.93	-17	-14	-15	-10	-13	-8.66	-12	-10	-9.20	-6.17
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-6.25	-18	-14	-15	-10	-12	-8.18	-11	-9.77	-8.65	-5.61
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.36	0.63	0.43	1.14	3.73	0.00	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.36	0.64	0.44	1.20	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.35	0.40	0.19	0.23	0.26	0.15	0.09	0.09	0.07	0.08	0.08
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.03	1.13	1.90	1.92	2.05	1.76	3.13	3.11	4.20
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.01	0.25	0.40	0.45	0.52	0.43	0.45	0.59	0.59
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.85	1.35	1.85	3.73	10.02	-10.30	-3.69	-7.17	-2.71	-2.21	-1.78
Long-Term Debt to Equity	0.85	1.35	1.85	3.73	10.02	-9.64	-3.46	-0.35	-0.13	-0.09	0.00
Financial Leverage	-1.00	-0.92	-0.84	-0.76	-0.72	-0.10	2.01	4.62	-2.97	-2.10	-1.73
Leverage Ratio	1.57	1.73	1.88	2.16	3.57	5.96	13.24	26.03	-11.20	-4.37	-2.60
Compound Leverage Factor	1.87	1.86	2.06	2.35	4.02	6.55	15.15	28.81	-12.55	-5.04	-3.22
Debt to Total Capital	45.84%	57.37%	64.93%	78.87%	90.93%	110.75%	137.16%	116.22%	158.48%	182.87%	227.57%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	7.06%	8.65%	110.56%	150.99%	175.79%	227.57%
Long-Term Debt to Total Capital	45.84%	57.37%	64.93%	78.87%	90.93%	103.70%	128.51%	5.65%	7.50%	7.09%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	54.16%	42.63%	35.07%	21.13%	9.07%	-10.75%	-37.16%	-16.22%	-58.48%	-82.87%	-127.57%
Debt to EBITDA	-1.20	-1.02	-0.94	-0.86	-0.79	-0.91	-1.05	-1.14	-1.09	-1.35	-1.40
Net Debt to EBITDA	1.37	0.57	0.21	-0.02	-0.16	-0.41	-0.70	-0.58	-0.65	-0.97	-1.09
Long-Term Debt to EBITDA	-1.20	-1.02	-0.94	-0.86	-0.79	-0.86	-0.98	-0.06	-0.05	-0.05	0.00
Debt to NOPAT	-1.39	-1.25	-1.16	-1.11	-1.14	-1.31	-1.45	-1.62	-1.52	-1.85	-2.01
Net Debt to NOPAT	1.59	0.70	0.26	-0.03	-0.23	-0.59	-0.98	-0.83	-0.90	-1.33	-1.56
Long-Term Debt to NOPAT	-1.39	-1.25	-1.16	-1.11	-1.14	-1.23	-1.36	-0.08	-0.07	-0.07	0.00
Altman Z-Score	-2.32	-3.51	-4.30	-5.07	-5.25	-6.57	-8.93	-8.52	-10.01	-11.34	-12.31
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	7.88	7.25	5.29	3.73	2.83	2.09	0.58	0.67	0.57	0.47	0.41
Quick Ratio	7.33	6.35	4.56	3.20	2.37	1.65	0.43	0.52	0.44	0.36	0.31
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-11	-21	-24	-18	-19	-16	-13	-11	-3.87	-3.17	3.52
Operating Cash Flow to CapEx	-3,669.93%	-1,819.01%	-481.90%	-191.86%	-501.30%	-4,664.71%	-1,952.10%	-558.78%	0.00%	-53,010.53%	-3,237.04%
Free Cash Flow to Firm to Interest Expense	-10.10	-15.32	-17.95	-13.54	-14.75	-13.23	-10.13	-8.48	-3.09	-2.23	2.41
Operating Cash Flow to Interest Expense	-9.68	-15.39	-9.49	-5.31	-6.22	-8.36	-8.17	-4.12	-4.35	-7.07	-2.39
Operating Cash Flow Less CapEx to Interest Expense	-9.95	-16.23	-11.46	-8.08	-7.46	-8.54	-8.59	-4.85	-4.32	-7.09	-2.46
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.48	0.53	0.62	0.74	0.67	0.86	1.03	1.00	1.05	1.19	1.43
Accounts Receivable Turnover	8.28	8.36	7.22	7.29	6.58	7.48	7.43	7.46	6.86	6.60	7.13
Inventory Turnover	2.02	1.53	1.54	1.62	1.41	1.34	1.65	1.75	1.80	1.86	2.18
Fixed Asset Turnover	32.59	18.01	12.56	10.90	10.80	10.10	8.96	7.61	7.68	7.99	8.71
Accounts Payable Turnover	2.29	1.85	1.89	2.39	1.80	1.58	2.06	1.91	1.68	1.70	2.04
Days Sales Outstanding (DSO)	44.06	43.66	50.59	50.08	55.49	48.78	49.12	48.93	53.19	55.32	51.18
Days Inventory Outstanding (DIO)	181.12	238.88	236.62	224.81	258.18	272.79	220.84	208.86	202.48	196.41	167.76
Days Payable Outstanding (DPO)	159.39	196.93	193.62	152.74	202.43	230.52	177.07	190.64	217.58	215.16	179.10
Cash Conversion Cycle (CCC)	65.79	85.61	93.59	122.15	111.24	91.05	92.88	67.15	38.10	36.57	39.84
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1.51	8.65	14	13	14	17	19	18	10	14	11
Invested Capital Turnover	349.43	11.83	7.21	6.61	8.45	5.66	4.52	4.63	5.97	4.76	5.09
Increase / (Decrease) in Invested Capital	2.74	8.73	13	8.74	12	8.04	4.88	4.35	-3.42	-2.99	-8.32
Enterprise Value (EV)	-30	-3.87	0.43	15	26	32	39	31	32	43	45
Market Capitalization	18	20	10	14	17	11	6.99	6.80	5.26	5.67	6.36
Book Value per Share	$1.92	$1.27	$0.93	$0.47	$0.17	($0.17)	($0.49)	($0.25)	($0.55)	($0.76)	($0.90)
Tangible Book Value per Share	$1.90	$1.25	$0.91	$0.45	($0.04)	($0.38)	($0.69)	($0.45)	($0.73)	($0.93)	($1.08)
Total Capital	91	76	68	58	50	43	35	41	28	28	22
Total Debt	42	44	44	46	45	47	48	48	45	51	50
Total Long-Term Debt	42	44	44	46	45	44	45	2.32	2.14	1.98	0.00
Net Debt	-48	-24	-9.79	1.22	9.20	21	32	24	27	37	39
Capital Expenditures (CapEx)	0.30	1.15	2.65	3.76	1.61	0.22	0.52	0.93	-0.04	0.02	0.11
Debt-free, Cash-free Net Working Capital (DFCFNWC)	1.75	5.94	5.12	2.38	0.96	2.19	-39	1.67	-2.39	-0.15	-1.80
Debt-free Net Working Capital (DFNWC)	91	74	59	47	37	28	-23	25	16	14	9.34
Net Working Capital (NWC)	91	74	59	47	37	25	-26	-20	-27	-35	-40
Net Nonoperating Expense (NNE)	-1.53	6.61	4.46	6.54	4.62	5.58	2.12	6.78	4.34	4.45	2.86
Net Nonoperating Obligations (NNO)	-48	-24	-9.79	1.22	9.20	21	32	24	27	37	39
Total Depreciation and Amortization (D&A)	-0.31	-0.47	-0.27	-0.02	0.21	0.39	0.49	0.54	0.62	0.55	0.56
Debt-free, Cash-free Net Working Capital to Revenue	3.49%	11.72%	9.45%	3.96%	1.49%	3.06%	-52.13%	2.31%	-3.33%	-0.20%	-2.37%
Debt-free Net Working Capital to Revenue	181.10%	146.21%	109.29%	77.92%	57.34%	39.09%	-31.18%	34.51%	22.06%	19.51%	12.35%
Net Working Capital to Revenue	181.10%	146.21%	109.29%	77.92%	57.34%	34.90%	-35.19%	-28.27%	-37.97%	-48.41%	-53.31%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.28)	($0.73)	($0.60)	($0.62)	($0.44)	($0.53)	($0.38)	($0.46)	($0.37)	($0.35)	($0.25)
Adjusted Weighted Average Basic Shares Outstanding	25.33M	25.64M	25.76M	25.98M	25.88M	26.25M	26.37M	28.39M	27.86M	30.54M	30.75M
Adjusted Diluted Earnings per Share	($0.28)	($0.73)	($0.60)	($0.62)	($0.44)	($0.53)	($0.38)	($0.46)	($0.37)	($0.35)	($0.25)
Adjusted Weighted Average Diluted Shares Outstanding	25.33M	25.64M	25.76M	25.98M	25.88M	26.25M	26.37M	28.39M	27.86M	30.54M	30.75M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	25.71M	25.80M	25.99M	26.22M	26.36M	26.43M	26.62M	30.49M	30.63M	30.78M	30.93M
Normalized Net Operating Profit after Tax (NOPAT)	-8.59	-12	-11	-9.66	-6.97	-8.28	-7.80	-6.41	-7.28	-6.16	-4.80
Normalized NOPAT Margin	-60.52%	-108.47%	-71.98%	-49.44%	-37.87%	-44.72%	-42.37%	-37.55%	-41.35%	-32.01%	-22.11%
Pre Tax Income Margin	-49.69%	-167.76%	-101.09%	-83.05%	-62.86%	-74.81%	-53.84%	-77.20%	-66.06%	-55.18%	-35.16%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-5.29	-12.74	-10.40	-10.94	-7.91	-10.23	-6.92	-9.39	-8.30	-6.46	-4.22
NOPAT to Interest Expense	-7.66	-8.88	-8.12	-7.11	-5.37	-6.71	-6.23	-5.05	-5.82	-4.33	-3.28
EBIT Less CapEx to Interest Expense	-5.55	-13.58	-12.37	-13.71	-9.15	-10.41	-7.34	-10.12	-8.27	-6.47	-4.29
NOPAT Less CapEx to Interest Expense	-7.92	-9.73	-10.09	-9.88	-6.61	-6.89	-6.65	-5.79	-5.79	-4.34	-3.35
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Avita Medical’s latest quarter shows modest revenue growth, but profitability remains deeply negative and the balance sheet has become more leveraged over the past year. In Q1 2026, revenue rose to $19.3 million from $17.6 million in Q4 2025 and $18.5 million in Q1 2025, but operating losses continued and cash declined slightly despite a financing boost.

Revenue improved sequentially and year over year. Q1 2026 revenue increased 9.3% from Q4 2025 and was roughly flat to slightly higher than Q1 2025, suggesting the top line is still moving in the right direction.
Gross profit remained healthy. Q1 2026 gross profit was $15.7 million on $19.3 million of revenue, implying a strong gross margin profile for a medical device company.
Operating cash flow improved versus late 2025. Operating cash outflow was $10.1 million in Q1 2026, better than the $5.4 million outflow in Q4 2025? Actually, Q1 was still negative, but it did improve sharply from the much larger annualized burn seen earlier in 2024.
The company has reduced some operating leverage compared with 2024. Revenue is higher than the same period last year, while quarterly net losses are not materially worse, which suggests some progress in scaling the business.
Cash and investments still provide a cushion. As of Q1 2026, Avita Medical held $8.3 million in cash and $5.95 million in short-term investments, giving it liquidity beyond just cash on hand.
Investing cash flow was positive in Q1 2026 because of investment sales. The company generated $2.0 million of net investing cash flow, but this was driven mainly by sales/maturities of investments rather than core business strength.
Interest expense remains a meaningful drag. Q1 2026 interest expense was $1.4 million, which is sizable relative to revenue and adds pressure to an already loss-making business.
Losses remain substantial. Q1 2026 net loss was $10.6 million, or $0.35 per share, indicating the company is still far from profitability.
Operating cash flow is still negative. Avita burned $10.1 million in operating cash during Q1 2026, so the business continues to rely on external financing and investment proceeds.
Debt burden increased materially over the last year. Short-term debt rose to $49.1 million in Q1 2026 from $3.0 million in Q2 2025, while total liabilities climbed to $74.7 million, pressuring the balance sheet.
Shareholders’ equity remains negative. Total common equity was a deficit of $23.2 million in Q1 2026, compared with a positive $32.6 million in Q1 2024, reflecting accumulated losses and a weaker capital structure.
Marketing spend remains very high. In Q1 2026, marketing expense was $12.8 million, larger than SG&A and a major contributor to the operating loss.

Bottom line: Avita Medical is showing some revenue momentum and still has liquidity, but the company remains unprofitable, cash flow negative, and more dependent on debt than it was a year ago. Investors will likely want to see sustained revenue growth and a meaningful reduction in operating losses before the financial picture looks materially better.

08/20/26 09:52 PM ETAI Generated. May Contain Errors.

Avita Medical Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Avita Medical's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Avita Medical's net income appears to be on an upward trend, with a most recent value of -$48.59 million in 2025, rising from -$9.05 million in 2017. The previous period was -$61.85 million in 2024. See where experts think Avita Medical is headed by visiting Avita Medical's forecast page.

Avita Medical's total operating income in 2025 was -$42.53 million, based on the following breakdown:

Total Gross Profit: $58.82 million
Total Operating Expenses: $101.35 million

Over the last 8 years, Avita Medical's total revenue changed from $0.00 in 2017 to $71.61 million in 2025, a change of 7,161,000,000.0%.

Avita Medical's total liabilities were at $73.04 million at the end of 2025, a 2.6% decrease from 2024, and a 2,352.6% increase since 2018.

In the past 7 years, Avita Medical's cash and equivalents has ranged from $10.24 million in 2025 to $73.64 million in 2020, and is currently $10.24 million as of their latest financial filing in 2025.

Over the last 8 years, Avita Medical's book value per share changed from 0.00 in 2017 to -0.55 in 2025, a change of -54.6%.

Related Companies

Financial statements for NASDAQ:RCEL last updated on 8/7/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avita Medical (RCEL) Financials

Financials Breakdown Chart

Key Financial Trends

Avita Medical Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avita Medical (RCEL) Financials

Annual Income Statements for Avita Medical

Quarterly Income Statements for Avita Medical

Annual Cash Flow Statements for Avita Medical

Quarterly Cash Flow Statements for Avita Medical

Annual Balance Sheets for Avita Medical

Quarterly Balance Sheets for Avita Medical

Annual Metrics And Ratios for Avita Medical

Quarterly Metrics And Ratios for Avita Medical

Financials Breakdown Chart

Key Financial Trends

Avita Medical Financials - Frequently Asked Questions

When does Avita Medical's financial year end?

How has Avita Medical's net income changed over the last 8 years?

What is Avita Medical's operating income?

How has Avita Medical's revenue changed over the last 8 years?

How much debt does Avita Medical have?

How much cash does Avita Medical have?

How has Avita Medical's book value per share changed over the last 8 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools